Objective:
To evaluate 2-year real-world clinical and anatomic outcomes in faricimab-treated patients with wet age-related macular degeneration (AMD).
Key Findings:
- Stable vision maintained in both treatment-naïve and previously treated groups over 2 years.
- Anatomic improvement observed in both groups.
- Average reduction in the number of injections required after the initial treatment period.
- Increased injection intervals by approximately 4 to 5 weeks after switching to faricimab in previously treated patients.
- Low rates of endophthalmitis (<0.1%) and intraocular inflammation (<0.5%).
Interpretation:
The findings support the effectiveness, safety, and durability of faricimab treatment for neovascular AMD in a diverse real-world population.
Limitations:
- Retrospective nature of the study may introduce biases.
- Data derived from a registry may not capture all variables influencing outcomes.
Conclusion:
The FARETINA study indicates that faricimab is effective in maintaining vision and improving anatomy while reducing treatment burden in neovascular AMD patients.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.